Repare Therapeutics Inc. entered into a definitive agreement to be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. The deal values each outstanding common share at an estimated $1.82 in cash at closing, and includes a non‑transferable contingent value right (CVR) that entitles holders to a share of future proceeds from existing partnerships and potential asset dispositions. A $2 million termination fee is payable by Repare if the transaction is terminated under specified circumstances. The transaction is expected to close in the first quarter of 2026, after which Repare will become a privately held company and its shares will be delisted from Nasdaq.
Continue reading for full analysis...